In-house research team
Our scientists run their own peptide programs across formulation, pharmacology and delivery, rather than licensing another company's work and reselling it.
The research side of the business
Research
Lab.
In-house science.
Patentable IP.
pep'd™ research.
Computational Discovery
We work with a computational research partner whose platform maps a peptide's biological signature against thousands of human and rare-disease signatures to identify where it may be most useful.
A shorter path to filing
Evidence-weighted shortlists come back in minutes rather than quarters, which shortens the work between an early signal and a defensible patent filing.
Findings inform the products
Each read-out points in two directions: new indications worth pursuing, and better formulations for the treatments patients can access today.
Why IP mattersIntellectual
Intellectual
property.
Peptides that have been in use for years can still carry unclaimed science. Where our research identifies it, four categories of protection apply, each eligible for a fresh 20-year patent term.
Our model is to develop the intellectual property in-house, prove it out, then partner or license with larger pharmaceutical companies who can take it through later-stage development.
New indications
Where a known peptide may treat a condition nobody has claimed it for.
Combination strategies
Pairings that outperform either molecule on its own.
Solid-form compositions
Cocrystals and solid forms that address bioavailability and consistency gaps.
Compositions of matter
Novel formulations, the strongest form of pharmaceutical protection.
Current
programs.
Three active programs. One peptide has already produced findings we believe are eligible for protection.
Program 01Program started
Half-life extension
A slow-release formulation designed to hold therapeutic levels for a week per injection.
Program 02Approach defined
Lipophilicity optimization
Improving how much of a dose reaches target tissue, so lower doses can do more.
Program 03Approach defined
Peptide delivery system
A delivery format free of microplastics and heavy metals, and easier for patients to use.
Program 01 · Half-life extensionHalf-life
Half-life
extension.
Most compounded peptides clear the body within hours, so patients self-inject around five times a week. Adherence tends to drop off as the schedule becomes harder to keep.
Program 01 targets a slow-release formulation that holds therapeutic concentration for a full week from a single injection. The molecule is unchanged. The result is fewer injections, steadier exposure, and a novel composition eligible for its own patent filing.
Standard peptide, 5x weekly dosing
Illustrative. Serum level spikes and troughs between doses.
Program 01 slow-release, 1x weekly
Illustrative. Concentration holds inside the therapeutic band.
- ~5x
- Fewer injectionsAbout 4 per month instead of 22, or roughly 13 versus 64 over 90 days.
- ~50%
- Higher mean exposureA steadier serum profile that stays inside the therapeutic band.
Charts are illustrative models of dosing frequency and exposure, not clinical trial data.
First read-outFirst
First
read-out.
- 01 · The run
PD01
An aged mouse myoblast signature mapped against more than 3,300 human disease and rare-disease signatures.
- 02 · The hit
A strong link to gastroparesis
Ranked #2 of 232 significant hits, and replicated across two independent patient cohorts. Secondary themes: fibrotic disease, cardiomyopathy and mitochondrial neurodegeneration.
- 03 · Why it matters
Relevance to GLP-1 use
Slowed gastric emptying is part of how GLP-1s work. As GLP-1 use grows toward 100 million people, so does the number of patients affected, and there is no peptide-based treatment available at that scale.
Top ranked hits
- ALS5.88
- Gastroparesis (high BMI)5.73
- Gastroparesis (low BMI)5.16
- Alzheimer's (early-onset familial)4.77
- Breast cancer4.40
- Aortic disease4.35
- Psoriasis3.95
- Sepsis3.88
- Osteoarthritis3.77
- Endometriosis3.71
Connectivity score. A higher bar indicates a stronger reversal of the disease signature.
Our research programs are pre-clinical. Nothing on this page is a claim that any pep'd treatment diagnoses, treats, cures or prevents any disease.
Research engine / Using AI to speed up IP discoveryAI-accelerated
Computational discovery partnership Case study · April 2026
AI-accelerated
IP discovery.
A peptide-exclusive partnership.
- Proprietary AI agents trained on our peptide library.
- Matches peptides to high-potential indications and combinations.
- Faster, sharper research decisions.
- A defensible head start competitors cannot copy.
0+
human disease signatures
<0 min
per peptide shortlist
PD01 read-out: gastroparesis.
- Our computational screen surfaced a non-obvious indication match for PD01.
- Strong signal toward GLP-1 linked gastroparesis.
- Market expands with every new GLP-1 patient.
Research enquiries
We welcome conversations with researchers, clinicians and potential development partners.